Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18912013 | 0.81 | RAB9A (0.51) | RAB9ANPC1ALDH1A1TSHRMAPT | |
| SCHEMBL28394986 | 0.79 | P2RX7 (0.43) | RAB9ANPC1ALDH1A1TSHRMAPT | |
| SCHEMBL4877890 | 0.76 | DRD3 (0.34) | TSHRMAPTP2RX7 | |
| SCHEMBL18905853 | 0.76 | MEN1 (0.48) | RAB9ANPC1ALDH1A1TSHRMAPT | |
| SCHEMBL1544336 | 0.75 | NPC1 (0.55) | RAB9ANPC1ALDH1A1TSHRMAPT | |
| SCHEMBL17725124 | 0.75 | CYP11B1 (0.32) | — | |
| SCHEMBL30396221 | 0.75 | NPC1 (0.55) | RAB9ANPC1ALDH1A1TSHRMAPT | |
| SCHEMBL18453413 | 0.74 | GSK3B (0.39) | — | |
| SCHEMBL17725273 | 0.70 | — | — | |
| SCHEMBL1544974 | 0.70 | ALDH1A1 (0.50) | RAB9AALDH1A1TSHRMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | INDIVIOR UK LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | INDIVIOR UK LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
| WO-2017064488-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LIMITED (GB) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017021920-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017021920-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| WO-2016067043-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2016-05-06 | — | — | WO | disclosed |
| US-7465744-B2 | Triazole compounds and the therapeutic use thereof | ABBOTT GMBH & CO. KG (DE) | 2008-12-16 | — | — | US | disclosed |
| EP-1594861-B1 | TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF | ABBOTT GMBH & CO KG (DE) | 2008-06-18 | — | — | EP | disclosed |
| US-20060241137-A1 | Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-26 | — | — | US | disclosed |
| US-6472392-B1 | Triazole compounds and the use thereof as dopamine-D3 -ligands | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| EP-0994865-B1 | TRIAZOLE COMPOUNDS AND THE USE THEREOF AS DOPAMINE-D 3-LIGANDS | BASF AG (DE) | 2002-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | DRD3, DRD2, SLC6A3 | RAB9A 470/4885NPC1 2568/4885ALDH1A1 620/4885 |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | RAB9A 1000/4885NPC1 3367/4885ALDH1A1 1368/4885 |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | RAB9A 1000/4885NPC1 3367/4885ALDH1A1 1368/4885 |
| US-20060241137-A1 | Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline | DRD3, SLC6A3, ADORA3 | RAB9A 3232/4885NPC1 1494/4885ALDH1A1 1075/4885 |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | DRD3, DRD2, SLC6A3 | RAB9A 875/4885NPC1 2781/4885ALDH1A1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.